Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. operates within the regenerative medicine sector, focusing on advanced wound care and sports medicine solutions, and has shown a potential for improved financial performance despite mixed results attributed to market dynamics and reimbursement uncertainties. The company is expected to benefit from structural changes in reimbursement, as indicated by a modest increase in the rate set for 2026, which could drive operating profits higher in the long run. Furthermore, with shares currently trading at a discount compared to peers, there is a positive outlook for valuation improvements as the company continues to deliver solid results and navigate the consolidating market effectively.

Bears say

The financial outlook for Organogenesis Holdings Inc. is clouded by several significant challenges that contribute to a negative perspective on the stock. Key concerns include the potential for lower-than-expected growth of the PuraPly product line, adverse impacts from Medicare Part B pricing on amniotic products, and competitive pressures from rivals that may overcome regulatory hurdles more swiftly. Additionally, risks are heightened by anticipated reductions in sales force sizes, which could lead to decreased commissions and pressures on profit margins, further compounding the challenges faced by the company in achieving expected financial performance.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.